Long-term outcome after endovascular treatment of cavernous sinus dural arteriovenous fistula and a literature review

• Published in: Acta neurochirurgica Vol. 159; no. 11; pp. 2113 - 2122
• Main Authors: Nishimuta, Yosuke, Awa, Ryuji, Sugata, Sei, Nagayama, Tetsuya, Makiuchi, Tsuneo, Tomosugi, Tetsuzo, Hanaya, Ryosuke, Tokimura, Hiroshi, Hirano, Hirofumi, Moinuddin, F. M., Kamil, Muhammad, Kibe, Akari, Arita, Kazunori
• Format: Journal Article
• Language: English
• Published: Vienna Springer Vienna 01.11.2017; Springer Nature B.V
• Subjects: Aged; Angiography; Angiography, Digital Subtraction; Brain stem; Bypasses; Cardiovascular system; Cavernous Sinus - diagnostic imaging; Cavernous Sinus - surgery; Central Nervous System Vascular Malformations - complications; Central Nervous System Vascular Malformations - diagnostic imaging; Central Nervous System Vascular Malformations - therapy; Cortex; Edema - etiology; Embolization; Embolization, Therapeutic - methods; Endovascular Procedures; Female; Fistulae; Humans; Infarction; Interventional Radiology; Literature reviews; Male; Medicine; Medicine & Public Health; Middle Aged; Minimally Invasive Surgery; Morbidity; Neurology; Neuroradiology; Neurosurgery; Original Article - Vascular; Paralysis; Radiosurgery; Retreatment; Retrospective Studies; Shunts; Sinus; Sinuses; Surgery; Surgical Orthopedics; Tinnitus; Treatment Outcome; Cavernous sinus dural AVF; Endovascular treatment; Arterio-venous fistula; Transvenous embolization; Coil
• ISSN: 0001-6268; 0942-0940
• DOI: 10.1007/s00701-017-3336-4

Background The long-term efficacy of endovascular treatment (EVT) for cavernous sinus dural arteriovenous fistulae (CS-dAVF) was assessed with a special focus on residual shunts after initial EVT. Patients and methods This retrospective survey included 50 patients who had undergone EVT and were followed for 1 month or longer (median follow-up 56 months). Results Common preoperative symptoms were chemosis (78%), extra-ocular motor palsy (72%), exophthalmos (66%), and tinnitus (26%). CS-dAVF were addressed by transvenous embolization (tVE, n  = 48), tVE only was used in 43 instances and tVE plus transarterial embolization (tAE) in five. Two patients underwent tAE only. Procedure-related morbidity (brainstem infarction) was recorded in one patient (2%) and transient symptom exacerbation (paradoxical worsening) in 12 patients (24%). Postoperative digital subtraction angiography showed no major retrograde shunt or cortical venous reflux in any of the 50 patients. Anterograde or minor retrograde residual shunt was observed in 17 patients (34%); three of these underwent additional tVE and four had Gamma Knife surgery. The shunt flow disappeared in all 17 patients 12.6 ± 13.4 (mean ± SD) months after initial EVT. At the latest follow-up, 65.7 ± 52.6 months after the initial operation, no shunt flow was observed in any of the 50 patients. None had remaining or newly developed chemosis or tinnitus on follow-up. The rate of persistent cavernous sinus symptoms at the latest follow-up was higher in patients with than without post-procedural paradoxical worsening (5/12, 41.7% vs. 2/38, 5.3%, p  = 0.0059 by Fisher’s exact test). Conclusions Long-term follow-up showed that EVT, especially tVE, is an efficient and safe treatment for CS-dAVF. It resulted in the eventual disappearance of shunt flow. Residual shunt without major retrograde flow or cortical venous reflux can be monitored without additional treatment.